Compare CINT & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CINT | QTTB |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 431.3M | 450.1M |
| IPO Year | 2021 | 2018 |
| Metric | CINT | QTTB |
|---|---|---|
| Price | $3.45 | $15.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $7.35 | ★ $13.00 |
| AVG Volume (30 Days) | 84.2K | ★ 403.3K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 136.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $53,737,000.00 |
| Revenue This Year | $16.69 | N/A |
| Revenue Next Year | $11.28 | N/A |
| P/E Ratio | $17.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.03 | $1.62 |
| 52 Week High | $6.06 | $23.57 |
| Indicator | CINT | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 46.80 | 51.96 |
| Support Level | $3.15 | $14.44 |
| Resistance Level | $3.59 | $16.78 |
| Average True Range (ATR) | 0.20 | 0.72 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 28.99 | 44.52 |
CI&T Inc operates as a partner in tech-integrated business solutions, helping organizations address complex challenges by integrating business approach, technology, and artificial intelligence into a single, coherent operating model. It is mainly engaged in the development of customizable software through the implementation of software solutions, including machine learning, artificial intelligence, data analytics, cloud migration and mobility technologies. The company provides technology services to various industry verticals, including Financial Services, Consumer Goods, Technology and Communications, Retail and Industrial Goods, Life Sciences, among others. The majority of the revenue is derived from providing technology services. Geographically, maximum revenue is derived from Brazil.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).